Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance
“We are pleased to finalize this agreement, a true win-win transaction providing value for both companies,” said
Under the terms of the Agreement,
Additional details can be found in Assertio’s Form 8-Ks filed with the
The Company is also pleased to announce a strong finish to the year with 2019 Neurology Franchise net sales expected to be above the upper end of the company’s previously expressed guidance of
Gralise® is a is a prescription medicine used to treat pain after shingles, or postherpetic neuralgia (PHN).
Learn more about
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results, including for 2019, to differ materially from those estimated, projected or anticipated, including expectations regarding royalties to be received based on sales of NUCYNTA® and NUCYNTA® ER, risks related to regulatory approval and clinical development of long-acting cosyntropin, expectations regarding potential business opportunities, and other risks outlined in the Company's public filings with the
Investor and Media Contact:
Senior Vice President and Chief Financial Officer
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.